Advertisement
Canada markets closed
  • S&P/TSX

    22,269.12
    +197.41 (+0.89%)
     
  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     
  • DOW

    38,686.32
    +574.84 (+1.51%)
     
  • CAD/USD

    0.7339
    +0.0028 (+0.38%)
     
  • CRUDE OIL

    77.18
    -0.73 (-0.94%)
     
  • Bitcoin CAD

    92,306.14
    +1,116.69 (+1.22%)
     
  • CMC Crypto 200

    1,425.77
    -2.80 (-0.20%)
     
  • GOLD FUTURES

    2,347.70
    -18.80 (-0.79%)
     
  • RUSSELL 2000

    2,070.13
    +13.53 (+0.66%)
     
  • 10-Yr Bond

    4.5140
    -0.0400 (-0.88%)
     
  • NASDAQ

    16,735.02
    -2.06 (-0.01%)
     
  • VOLATILITY

    12.92
    -1.55 (-10.71%)
     
  • FTSE

    8,275.38
    +44.33 (+0.54%)
     
  • NIKKEI 225

    38,487.90
    +433.77 (+1.14%)
     
  • CAD/EUR

    0.6762
    +0.0016 (+0.24%)
     

PlantX Announces Proposed Share Consolidation

VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- PlantX Life Inc. (CSE: VEGA, FRA: WNT1) (the “Company”) will complete a consolidation of the authorized and issued common shares of the Company (the “Common Shares”) on the basis of one post-consolidated Common Share for each fifty pre-consolidated Common Shares (the “Consolidation”).

Prior to the Consolidation, the Company had 34,423,688 pre-Consolidation Common Shares issued and outstanding. Following the Consolidation, the Company will have approximately 688,473 post-Consolidation Common Shares issued and outstanding. No fractional Common Shares will be issued upon the Consolidation. In the event a holder of Common Shares would otherwise be entitled to receive a fractional Common Share in connection with the Consolidation, the number of Common Shares to be received by such shareholder will be rounded down to the next whole number.

The Consolidation was approved by the Company’s shareholders at the annual general and special meeting of the Company’s shareholders held on May 3, 2024. Outstanding PlantX stock options and share purchase warrants will also be adjusted by the Consolidation ratio and the respective exercise prices of outstanding options and share purchase warrants will be adjusted accordingly.

The record date of the Consolidation is May 23, 2024, and effective at the opening of markets on May 22, 2024, the Common Shares will commence trading on the Canadian Securities Exchange on a post-Consolidation basis under the existing ticker “VEGA”. The new CUSIP number will be 72750P600 and the new ISIN number will be CA72750P6003.

ADVERTISEMENT

The Consolidation is subject to the approval of the Canadian Securities Exchange (“CSE”).

For further information, please contact:
Lorne Rapkin
Chief Executive Officer
(416) 419-1415

Neither the Canadian Securities Exchange nor its Market Regulator (as the term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: (i) expectations regarding obtaining the approval of the CSE for the Consolidation and (ii) expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the approval of the CSE for the Consolidation. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company have attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and do not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.